Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

被引：0
|
作者：
Parrondo, Ricardo D. [1 ]
Laplant, Betsy R. [2 ]
Elliott, Jamie [1 ]
Fernandez, Andre [1 ]
Flott, Caitlin J. [1 ]
Arrington, Diedre [1 ]
Chapin, Dustin [1 ]
Brown, Jade [1 ]
Das, Saurav [1 ]
Roy, Vivek [1 ]
Chanan-Khan, Asher A. [1 ,3 ]
Ailawadhi, Sikander [1 ,3 ]
机构：
[1] Mayo Clin, Canc Ctr, Dept Hematol Oncol, Jacksonville, FL 32224 USA
[2] Mayo Clin, Quantitat Hlth Sci, Rochester, MN USA
[3] Mayo Clin, Ctr Canc, Dept Canc Biol, Jacksonville, FL 32224 USA
来源：
BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期
关键词：
D O I：
10.1038/s41408-024-01134-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
    Frerichs, Kristine A.
    Verkleij, Christie P. M.
    Dimopoulos, Meletios A.
    Marin Soto, Jhon A.
    Zweegman, Sonja
    Young, Mary H.
    Newhall, Kathryn J.
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    CANCERS, 2021, 13 (10)
  • [32] Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
    Suzanne Trudel
    Arleigh McCurdy
    Martha L. Louzada
    Stephen Parkin
    Darrell White
    Michael P. Chu
    Rami Kotb
    Hira Mian
    Ibraheem Othman
    Jiandong Su
    Aniba Khan
    Engin Gul
    Donna Reece
    Nature Medicine, 2024, 30 : 543 - 551
  • [33] A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Gasparetto, Cristina
    Bowles, Kristian M.
    Abdallah, Al-Ola
    Morris, Lura
    Mander, Gudrun
    Coppola, Sheryl
    Wang, Jing
    Ross, Jeremy A.
    Bueno, Orlando F.
    Arriola, Emma
    Mateos, Maria Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 775 - 784
  • [34] Daratumumab, Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naive Relapsed Refractory Multiple Myeloma Patients
    Ouchveridze, Evguenia
    Singh, Chandandeep
    Atrash, Shebli
    Paul, Barry
    Mohan, Meera
    Alkharabsheh, Omar
    Afrough, Aimaz
    Cui, Wei
    Mahmoudjafari, Zahra
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2022, 140 : 7164 - 7165
  • [35] Elotuzumab in Combination with Pomalidomide and Corticosteroids for Relapsed or Refractory Multiple Myeloma
    Sidiqi, Hasib
    McGregor, Scott
    Baker, Ross
    Carnley, Ben
    Radeski, Dejan
    Barraclough, Allison
    Augustson, Bradley
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E83 - E84
  • [36] Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma
    Hoylman, Emily
    Brown, Anna
    Perissinotti, Anthony J.
    Marini, Bernard L.
    Pianko, Matthew
    Ye, Jing Christine
    Campagnaro, Erica
    Nachar, Victoria R.
    LEUKEMIA & LYMPHOMA, 2020, 61 (03) : 691 - 698
  • [37] ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma Final Overall Survival Analysis
    Raab, Marc-Steffen
    Dimopoulos, Meletios
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    Leblanc, Richard
    Suzuki, Kenshi
    Richardson, Paul G.
    Mckiver, Mihaela Popa
    Jou, Ying-Ming
    Yao, David
    Das, Prianka
    San-Miguel, Jesus
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 174 - 174
  • [38] Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
    Takafumi Ide
    Mayu Osawa
    Kinjal Sanghavi
    Heather E. Vezina
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 129 - 140
  • [39] Daratumumab Combined with Pomalidomide and Dexamethasone (DPd) for Patients with Relapsed/Refractory Multiple Myeloma in a Single Institution
    Abdallah, Al-Ola
    McGuirk, Joseph P.
    Shune, Leyla
    Dunavin, Neil
    Mahmoudjafari, Zahra
    Hochard, Erica
    Ganguly, Siddhartha
    BLOOD, 2017, 130
  • [40] Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience
    Abdallah, Al-Ola
    Dunavin, Neil
    McClune, Brian
    Shune, Leyla
    Dias, Ajoy L.
    Mahmoudjafari, Zahra
    Hochard, Erica
    McGuirk, Joseph P.
    Ganguly, Siddhartha
    BLOOD, 2018, 132
12345